SCHEMBL26530409

SCHEMBL26530409

CC(F)c1nnc(-c2ccc(COc3ccncc3)nc2)o1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.46
ALDH1A1 P00352 5/20 0.46
NPC1 O15118 4/20 0.46
RAB9A P51151 4/20 0.46
HSD17B10 Q99714 4/20 0.46
HPGD P15428 4/20 0.46
LMNA P02545 2/20 0.46
TSHR P16473 2/20 0.46
HDAC6 Q9UBN7 10/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
CYP2C9 P11712 2/20 0.43
CYP2C19 P33261 2/20 0.43
MEN1 O00255 1/20 0.43
CYP1A2 P05177 1/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2D6 P10635 1/20 0.43
KMT2A Q03164 1/20 0.43
MAPT P10636 2/20 0.41
HDAC1 Q13547 1/20 0.38
SLC6A3 Q01959 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31336066 0.91 HDAC6 (0.52) KDM4EALDH1A1NPC1RAB9AHSD17B10
SCHEMBL26125149 0.91 HDAC6 (0.52) KDM4EALDH1A1NPC1RAB9AHSD17B10
SCHEMBL26530404 0.88 HDAC6 (0.46) NPC1RAB9AHDAC6
SCHEMBL26530545 0.88 HDAC6 (0.43) KDM4EALDH1A1NPC1RAB9AHSD17B10
SCHEMBL26530397 0.87 HDAC6 (0.52) KDM4EALDH1A1NPC1RAB9AHSD17B10
SCHEMBL26530507 0.87 HDAC6 (0.42) HPGDLMNATSHRHDAC6SMN1; SMN2
SCHEMBL26530439 0.85 HDAC6 (0.41) KDM4EALDH1A1NPC1RAB9AHSD17B10
SCHEMBL26530549 0.85 HDAC6 (0.41) KDM4EALDH1A1NPC1RAB9AHSD17B10
SCHEMBL26556026 0.85 HDAC6 (0.40) KDM4EALDH1A1NPC1RAB9AHSD17B10
SCHEMBL26530517 0.85 HDAC6 (0.46) HDAC6HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230322747-A1 OXADIAZOLE HDAC6 INHIBITORS AND USES THEREOF EIKONIZO THERAPEUTICS, INC. (US) 2023-10-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230322747-A1 OXADIAZOLE HDAC6 INHIBITORS AND USES THEREOF HDAC6, HDAC1, HDAC11 KDM4E 2674/4885ALDH1A1 755/4885NPC1 2177/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.